Asset profile
EMP16
Small molecule
Evidence outlook · lead readout
NCT04521751 · Overweight or Obesity
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT04521751: The study was a randomized, triple-masked, placebo-controlled trial with 156 participants, and its primary endpoint was the clinical measure of percentage change in body weight at 26 weeks. Because the primary comparison has no posted results, it cannot establish whether the endpoint was met; the available evidence therefore supports a moderate grade rather than a strong one.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.